The FDA announced the authorization the day after the agency’s panel of outside experts endorsed its use. Moderna said it intended to apply for full US license in 2021.
The decision marks the first regulatory authorization in the world for Moderna’s vaccine and validation of its messenger RNA technology. It came less than a year after the first Covid-19 case was identified in the United States.
The biotech company has worked with the US government to prepare for the distribution of 5.9 million shots as early as this weekend.
The FDA decision is based on results from a late-stage study of 30,000 volunteers that found the vaccine was nearly 95% effective at preventing illness from Covid-19 with no serious safety concerns.
The authorization follows an EUA granted for a similar vaccine from Pfizer Inc and German partner BioNTech SE that has been put into the arms of thousands of US healthcare workers this week in a massive nationwide rollout.
“With the availability of two vaccines now for the prevention of COVID-19, the FDA has taken another crucial step in the fight against this global pandemic that is causing vast numbers of hospitalizations and deaths in the United States each day,” FDA Commissioner Stephen M Hahn, MD, said in a statement.
Moderna’s shot is expected to be used in harder-to-reach locations, such as rural hospitals. The vaccine needs to be stored and shipped frozen, but does not require the ultra-cold temperatures of the Pfizer/BioNTech shot.
Once thawed, the Moderna vaccine can be kept at typical refrigerator temperatures. It is administered in two shots 28 days apart.
Moderna said it would deliver approximately 20 million doses to the US government this year and expected to have between 100 million and 125 million in the first quarter of next year, with 85-100 million of those for the United States.
Moderna has deals with the US government to provide a total of 200 million doses by the end of June 2021.